日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Plasma membrane-coated nanoparticles and membrane vesicles to orchestrate multimodal antitumor immunity

利用质膜包覆的纳米颗粒和膜囊泡来协调多模式抗肿瘤免疫

Ito, Yusuke; Kasuya, Hitomi; Kataoka, Mirei; Nakamura, Noriko; Yoshikawa, Toshiaki; Nakashima, Takahiro; Zhang, Haosong; Li, Yang; Matsukawa, Tetsuya; Inoue, Satoshi; Oneyama, Chitose; Ohta, Seiichi; Kagoya, Yuki

JAK-STAT-activated, fratricide-resistant CAR-T cells targeting membrane-bound TNF effectively treat AML and solid tumors.

靶向膜结合 TNF 的 JAK-STAT 激活的、具有抗同源杀伤能力的 CAR-T 细胞可有效治疗 AML 和实体瘤

Nakashima Takahiro, Ouchida Tsunenori, Ishikawa Yuichi, Ito Yusuke, Hayakawa Taeko, Yoshikawa Toshiaki, Zhang Haosong, Kasuya Hitomi, Li Yang, Matsukawa Tetsuya, Inoue Satoshi, Iida Shinsuke, Kiyoi Hitoshi, Kagoya Yuki

CD83 expression characterizes precursor exhausted T cell population

CD83表达是耗竭前体T细胞群的特征。

Wu, Zhiwen; Yoshikawa, Toshiaki; Inoue, Satoshi; Ito, Yusuke; Kasuya, Hitomi; Nakashima, Takahiro; Zhang, Haosong; Kotaka, Saki; Hosoda, Waki; Suzuki, Shiro; Kagoya, Yuki

Selection of highly responsive T cell receptors by an analysis combining the expression of multiple markers

通过结合多种标志物表达的分析来筛选高反应性T细胞受体

Thi Viet Ha, My; Hamana, Hiroshi; Shitaoka, Kiyomi; Hayee, Abdul; Kobayashi, Eiji; Yoshikawa, Toshiaki; Nakatsura, Tetsuya; Saikawa, Reiko; Sato, Eri; Osawa, Mitsujiro; Hitoshi, Yasumichi; Son Dang, Tung; Ozawa, Tatsuhiko; Kishi, Hiroyuki

Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis

肽疫苗作为糖蛋白-3阳性肝细胞癌的佐剂疗法,可诱导肽特异性CTL,并改善长期预后。

Taniguchi, Masatake; Mizuno, Shoichi; Yoshikawa, Toshiaki; Fujinami, Norihiro; Sugimoto, Motokazu; Kobayashi, Shin; Takahashi, Shinichiro; Konishi, Masaru; Gotohda, Naoto; Nakatsura, Tetsuya

First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

IT1208(一种去岩藻糖基化人源化抗CD4耗竭抗体)在晚期实体瘤患者中的首次人体I期研究

Shitara, Kohei; Ueha, Satoshi; Shichino, Shigeyuki; Aoki, Hiroyasu; Ogiwara, Haru; Nakatsura, Tetsuya; Suzuki, Toshihiro; Shimomura, Manami; Yoshikawa, Toshiaki; Shoda, Kayoko; Kitano, Shigehisa; Yamashita, Makiko; Nakayama, Takayuki; Sato, Akihiro; Kuroda, Sakiko; Wakabayashi, Masashi; Nomura, Shogo; Yokochi, Shoji; Ito, Satoru; Matsushima, Kouji; Doi, Toshihiko

Higher human lymphocyte antigen class I expression in early-stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes

早期癌细胞中人类淋巴细胞抗原I类分子的高表达导致其对细胞毒性T淋巴细胞的高度敏感性。

Akazawa, Yu; Nobuoka, Daisuke; Takahashi, Mari; Yoshikawa, Toshiaki; Shimomura, Manami; Mizuno, Shoichi; Fujiwara, Toshiyoshi; Nakamoto, Yasunari; Nakatsura, Tetsuya

Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial

热休克蛋白105肽疫苗在I期临床试验中可能诱导抗肿瘤免疫反应

Shimizu, Yasuhiro; Yoshikawa, Toshiaki; Kojima, Takashi; Shoda, Kayoko; Nosaka, Kazuto; Mizuno, Shoichi; Wada, Satoshi; Fujimoto, Yuki; Sasada, Tetsuro; Kohashi, Kenichi; Bando, Hideaki; Endo, Itaru; Nakatsura, Tetsuya

Efficacy of the NCCV Cocktail-1 vaccine for refractory pediatric solid tumors: A phase I clinical trial

NCCV Cocktail-1疫苗治疗难治性儿童实体瘤的疗效:一项I期临床试验

Akazawa, Yu; Hosono, Ako; Yoshikawa, Toshiaki; Kaneda, Hide; Nitani, Chika; Hara, Junichi; Kinoshita, Yoshiaki; Kohashi, Kenichi; Manabe, Atsushi; Fukutani, Miki; Wakabayashi, Masashi; Sato, Akihiro; Shoda, Kayoko; Shimomura, Manami; Mizuno, Shoichi; Nakamoto, Yasunari; Nakatsura, Tetsuya

Next-Generation Cancer Immunotherapy Targeting Glypican-3

靶向糖蛋白聚糖-3的下一代癌症免疫疗法

Shimizu, Yasuhiro; Suzuki, Toshihiro; Yoshikawa, Toshiaki; Endo, Itaru; Nakatsura, Tetsuya